Plaintiffs, victims of attacks by the terrorist group Jaysh al-Mahdi in Iraq, sued major pharmaceutical and medical equipment manufacturers under the Anti-Terrorism Act (ATA) and the Justice Against Sponsors of Terrorism Act (JASTA). The plaintiffs alleged that during the period when Jaysh al-Mahdi controlled Iraq's Ministry of Health, the defendants knowingly provided substantial assistance to the group by paying illegal cash bribes and supplying off-the-books medical goods. These funds and goods were allegedly used to finance the group's attacks against U.S. service members and civilians. The district court dismissed the case, ruling that the complaint failed to state a claim for aiding-and-abetting liability and that the court lacked personal jurisdiction over the foreign defendants. The D.C. Circuit previously reversed that dismissal, but the Supreme Court vacated the decision and remanded the case for reconsideration in light of its 2023 ruling in Twitter, Inc. v. Taamneh, which clarified the scope of secondary liability under the ATA.
The court analyzed the secondary liability claims under the framework established in Taamneh, which requires a showing of 'conscious, voluntary, and culpable participation' in another's tortious activity and a 'nexus' between the assistance and the specific acts of terrorism. The court distinguished the defendants' conduct from the passive, tangential assistance in Taamneh, noting that the pharmaceutical companies engaged in 'unusual and unlawful' business practices. Unlike the social media companies in Taamneh, which provided general services to everyone, the defendants here actively structured transactions to facilitate Jaysh al-Mahdi's operations, including paying 20 percent cash commissions and providing free goods that were diverted to the black market. The court found a sufficient nexus because the payments were made to a ministry openly controlled by the terrorist group, and the attacks were a 'natural and virtually inevitable consequence' of this specific, corrupt assistance. The court emphasized that the defendants' knowledge was established through firsthand reports from their local agents, widespread media coverage, and corporate security monitoring. Regarding direct liability, the court noted that Taamneh did not address the standard for direct liability under the ATA and therefore reinstated its prior holding that plaintiffs adequately pleaded proximate causation. Finally, the court reaffirmed its earlier holding that U.S. federal courts have personal jurisdiction over the foreign defendants, as the Supreme Court did not review that specific issue.
The decision allows the civil suit to proceed to trial, meaning the pharmaceutical companies must now face discovery and potential liability for aiding and abetting terrorism. The ruling clarifies that ordinary business transactions can trigger liability if they are conducted in an 'unusual way' that knowingly facilitates specific terrorist acts. The case is remanded to the district court to determine whether the defendants' conduct constitutes an 'act of international terrorism' for the purpose of direct liability, a question the Supreme Court did not address. The holding on personal jurisdiction remains in place, ensuring the foreign defendants can be sued in U.S. courts.
Podcast (federal-narrative-summaries): Play in new window | Download